1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology,...
-
Upload
tyler-walsh -
Category
Documents
-
view
223 -
download
0
Transcript of 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology,...
![Page 1: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/1.jpg)
1
Objectives, designand initial results from Phase I
Nils SchoofCorp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH
![Page 2: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/2.jpg)
Disclaimer
• GLORIA-AF is sponsored by Boehringer Ingelheim
• Nils Schoof is an employee of Boehringer Ingelheim
2
![Page 3: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/3.jpg)
Outline
• Background• Objectives• Study Population and Setting• Design• Methods• Initial results from Phase I
3
![Page 4: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/4.jpg)
Background
4
• Atrial fibrillation (AF) is the most common cardiac arrhythmia
• AF is affecting 1-2% of the population and raises the risk of stroke 5-fold.
• Vitamin K antagonists (VKA) were the gold standard treatment for about 5 decades
• New oral anticoagulants (NOACs), like dabigatran, are changing treatment patterns of AF patients
• GLORIA-AF is a large, international, observational registry program of patients with newly diagnosed AF at risk of stroke
![Page 5: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/5.jpg)
Objectives of GLORIA-AF
5
• To characterize patients newly diagnosed with non-valvular AF at risk for stroke in various regions of the world
• To describe current patterns of antithrombotic treatment
• To assess data on the safety and effectiveness of antithrombotic treatments
![Page 6: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/6.jpg)
Study Population and Setting of GLORIA-AF
6
• Up to 56,000 patients in up to 50 countries• Five regions: Asia, Europe, North America, Latin America and
Africa/Middle East
![Page 7: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/7.jpg)
Design of GLORIA-AF
7
Patients on dabigatran etexilate
Baseline Visit
Phase ICross-sectional analysis
All patients
Phase IICross-sectional, cohort, case-control analyses
Phase IIICross-sectional and comparative analyses
Baseline VisitBaseline Visit
3M 6M 1YR 2YR 6M 1YR 2YR 3YR
• Status:Currently ongoing
• Status:Ended Jan 2013
• Status:Start upon comparability of treatment groups in Phase II
![Page 8: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/8.jpg)
Initial results from Phase I
8
![Page 9: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/9.jpg)
Patient Disposition by Region (N=1063)
9
67%
27%
6%Asia (China)
Europe (Nether-lands, Spain, Germany, Croa-tia)
Middle East (Egypt, Lebanon, Turkey, UAE)
(N=291)(N=59)
(N=713)
![Page 10: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/10.jpg)
DemographicsSite Types by Region
10
Asia Europe Africa/Middle East
Number of sites 25 (100.0) 31 (100.0) 3 (100.0)
Type of site [N (%)]
GP/primary care
Specialist office
Community hospital
University hospital
Out-patient health care center
Anticoagulation clinics
Other
2 (8.0)
0 (0.0)
1 (4.0)
22 (88.0)
0 (0.0)
0 (0.0)
0 (0.0)
2 (6.5)
12 (38.7)
1 (3.2)
13 (41.9)
0 (0.0)
0 (0.0)
3 (9.7)
0 (0.0)
2 (66.7)
0 (0.0)
1 (33.3)
0 (0.0)
0 (0.0)
0 (0.0)
![Page 11: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/11.jpg)
Patient Demographics & Medical history (Asia)
11
Demographics AsiaN=713
EuropeN=291
Africa/Middle EastN=59
Age (years) Median (IQR) 69.0 (59.0-77.0) 71.0 (64.0-79.0) 65.0 (57.0-74.0)
Female N(%) 305 (42.8) 147 (50.5) 34 (57.6)
BMI Median (IQR) 23.9 (21.5-26.10) 28.1 (25.4-31.2) 27.3 (24.2-33.3)
![Page 12: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/12.jpg)
Patient Demographics & Medical history (Asia)
12
Medical History AsiaN=713 (100%)
EuropeN=291 (100%)
Africa/Middle EastN=59 (100%)
Previous stroke 73 (10.2) 31 (10.7) 6 (10.2)
Myocardial infarction (MI) 59 (8.3) 32 (11.0) 8 (13.6)
Coronary artery disease (CAD)
181 (25.4) 59 (20.3) 16 (27.1)
Congestive heart failure 176 (24.7) 65 (22.3) 15 (25.4)
History of hypertension 500 (70.1) 248 (85.2) 47 (79.7)
Diabetes mellitus 139 (19.5) 79 (27.1) 22 (37.3)
Chronic gastrointestinal diseases
61 (8.6) 9 (3.1) 3 (5.1)
![Page 13: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/13.jpg)
Stroke and bleeding risk scores (Asia)
13
AsiaN=713 (100%)
EuropeN=291 (100%)
Africa/Middle EastN=59 (100%)
CHADS2 score class Low (score=0) Moderate (score=1) High (score ≥2)
84 (11.8)270 (37.9)359 (50.4)
16 (5.5)95 (32.6)180 (61.9)
2 (3.4)21 (35.6)36 (61.0)
CHA2DS2VASC score class Low (score=0) Moderate (score=1) High (score ≥2)
0 184 (25.8)529 (74.2)
0 (0.0)36 (12.4)255 (87.6)
0 (0.0)6 (10.2)53 (89.8)
HAS-BLED score class Low (score <3) High (score ≥3) Missing
596 (83.6)88 (12.3)29 (4.1)
224 (77.0)23 (7.9)
44 (15.1)
40 (67.8)10 (16.9)9 (15.3)
![Page 14: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/14.jpg)
Comparison of AF patients characteristics (Asia)
DISCLAIMER: Studies differ in region, study period and in- & exclusion criteria * Assessed within a general population of 29079 individuals
GLORIA-AF Phase I:Asian population
AF population in China
(Zhou et al. 2008)
n=713 n=224*
Age (years) Mean (SD) 67.4 (12.7) 65.7 (11.0)
Female (%) 42.8 45.1
Comorbidities (%) Previous stroke Myocardial infarction Heart failure Hypertension Diabetes mellitus
10.28.3
24.770.119.5
13.0--
54.05.8
14
![Page 15: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/15.jpg)
Conclusions
• GLORIA-AF registry program addresses the need for data from routine clinical practice
• Enhancement of knowledge on the NOACs and in particular on dabigatran.
• Allows comparative analyses when comparability between treatment groups is reached to ensure efficient use of available information.
• Data collection from the time prior to NOACs entering the market (Phase I) was finished including 1063 patients with 67% of the patients from China
• High proportions of patients at high risk of stroke (CHA2DS2-VASc: 74.2%) and at low risk of bleeding (HAS-BLED: 83.6%) are present in China
15
![Page 16: 1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.](https://reader033.fdocuments.in/reader033/viewer/2022051001/56649ea35503460f94ba7f36/html5/thumbnails/16.jpg)
Acknowledgement
Scientific steering committee• MV Huisman, Leiden University Medical Center, Netherlands• GYH Lip, University of Birmingham, UK• HC Diener, Universitätsklinikum Essen, Germany• SJ Dubner, Clinica y Maternidad Suizo, Argentina• JL Halperin, Mount Sinai School of Medicine, USA• CS Ma, Beijing An Zhen Hospital, China• KJ Rothman, Harvard School of Public Health, USA
16
Boehringer Ingelheim Study team• D Ackermann• DB Bartels• A Clemens• E Kleine• Nicole Malek• Liz Nacar• M Parquette• C Teutsch• K Zint